Stock Analysis on Net
Stock Analysis on Net

Allergan PLC (NYSE:AGN)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Common-Size Income Statement
Quarterly Data

Paying user area

Try for free

Allergan PLC pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Allergan PLC, common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Net revenues
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights
Gross profit
Research and development
Selling and marketing
General and administrative
Amortization
Goodwill impairments
In-process research and development impairments
Asset sales and impairments, net
Operating income (loss)
Interest income
Interest expense
Other income (expense), net
Other income (expense), net
Income (loss) before income taxes and noncontrolling interest
(Provision) benefit for income taxes
Net income (loss) from continuing operations, net of tax
Income (loss) from discontinued operations, net of tax
Net income (loss)
(Income) loss attributable to noncontrolling interest
Net income (loss) attributable to shareholders
Dividends on preferred shares
Net income (loss) attributable to ordinary shareholders

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Allergan PLC operating income (loss) as a percentage of net revenues increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Income (loss) before income taxes and noncontrolling interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Allergan PLC income (loss) before income taxes and noncontrolling interest as a percentage of net revenues increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Net income (loss) attributable to shareholders The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Allergan PLC net income (loss) attributable to shareholders as a percentage of net revenues increased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.